376 related articles for article (PubMed ID: 17382711)
21. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
Jocham D; Witjes F; Wagner S; Zeylemaker B; van Moorselaar J; Grimm MO; Muschter R; Popken G; König F; Knüchel R; Kurth KH
J Urol; 2005 Sep; 174(3):862-6; discussion 866. PubMed ID: 16093971
[TBL] [Abstract][Full Text] [Related]
22. Urine cytology after flexible cystoscopy.
Herr HW; Regan M
BJU Int; 2005 Oct; 96(6):796-7. PubMed ID: 16153203
[TBL] [Abstract][Full Text] [Related]
23. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
Gupta NP; Sharma N; Kumar R
Urology; 2009 Mar; 73(3):592-6; discussion 596-7. PubMed ID: 19168205
[TBL] [Abstract][Full Text] [Related]
24. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
Babjuk M; Soukup V; Pesl M; Kostírová M; Drncová E; Smolová H; Szakacsová M; Getzenberg R; Pavlík I; Dvorácek J
Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400
[TBL] [Abstract][Full Text] [Related]
25. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
[TBL] [Abstract][Full Text] [Related]
26. [Value of the uCyt+ test for the detection and followup of bladder tumors].
Drapier E; Renaudin K; Maillet F; Braud G; Laboisse C; Bouchot O
Prog Urol; 2003 Apr; 13(2):222-6. PubMed ID: 12765055
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
[TBL] [Abstract][Full Text] [Related]
28. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
[TBL] [Abstract][Full Text] [Related]
29. A side by side comparison of cytology and biomarkers for bladder cancer detection.
Schroeder GL; Lorenzo-Gomez MF; Hautmann SH; Friedrich MG; Ekici S; Huland H; Lokeshwar V
J Urol; 2004 Sep; 172(3):1123-6. PubMed ID: 15311054
[TBL] [Abstract][Full Text] [Related]
30. Immediate versus delayed outpatient flexible cystoscopy: final report of a randomized study.
Herr HW; Schneider M
Can J Urol; 2001 Dec; 8(6):1406-8. PubMed ID: 11788018
[TBL] [Abstract][Full Text] [Related]
31. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer.
Gudjónsson S; Isfoss BL; Hansson K; Domanski AM; Warenholt J; Soller W; Lundberg LM; Liedberg F; Grabe M; Månsson W
Eur Urol; 2008 Aug; 54(2):402-8. PubMed ID: 18082934
[TBL] [Abstract][Full Text] [Related]
32. [Numerical aberrations of chromosomes 11 and 17 detected by fish--fluorescence in situ hybridization combined with cytology in exfoliated cells from voided urine in patients with urothelial carcinoma of the bladder].
Asali MG; Kaneti J; Manor E
Harefuah; 2007 Dec; 146(12):914-9, 1000. PubMed ID: 18254439
[TBL] [Abstract][Full Text] [Related]
33. Assessing the value of reflex fluorescence in situ hybridization testing in the diagnosis of bladder cancer when routine urine cytological examination is equivocal.
Kipp BR; Halling KC; Campion MB; Wendel AJ; Karnes RJ; Zhang J; Sebo TJ
J Urol; 2008 Apr; 179(4):1296-301; discussion 1301. PubMed ID: 18289582
[TBL] [Abstract][Full Text] [Related]
34. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?
Loidl W; Schmidbauer J; Susani M; Marberger M
Eur Urol; 2005 Mar; 47(3):323-6. PubMed ID: 15716195
[TBL] [Abstract][Full Text] [Related]
35. Inverted papilloma of urinary bladder: is long-term cystoscopic surveillance needed? A single center's experience.
Ho H; Chen YD; Tan PH; Wang M; Lau WK; Cheng C
Urology; 2006 Aug; 68(2):333-6. PubMed ID: 16904447
[TBL] [Abstract][Full Text] [Related]
36. [The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer].
Daniltchenko D; Riedl C; Koenig F; Daha LK; Sachs M; Schnorr D
Aktuelle Urol; 2004 Nov; 35(6):497-501. PubMed ID: 15526230
[TBL] [Abstract][Full Text] [Related]
37. Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance?
Yutkin V; Nisman B; Pode D
Expert Rev Anticancer Ther; 2010 Jun; 10(6):787-90. PubMed ID: 20553203
[No Abstract] [Full Text] [Related]
38. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer.
Black PC; Brown GA; Dinney CP
J Clin Oncol; 2006 Dec; 24(35):5528-35. PubMed ID: 17158538
[TBL] [Abstract][Full Text] [Related]
39. Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology.
Ray ER; Chatterton K; Khan MS; Thomas K; Chandra A; O'Brien TS
BJU Int; 2009 May; 103(10):1363-7. PubMed ID: 19076151
[TBL] [Abstract][Full Text] [Related]
40. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer.
Varella-Garcia M; Akduman B; Sunpaweravong P; Di Maria MV; Crawford ED
Urol Oncol; 2004; 22(1):16-9. PubMed ID: 14969798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
